Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Infinityon Apr 14, 2024 3:32pm
380 Views
Post# 35988357

Evaluable Patients

Evaluable PatientsI was just looking some previous MD & A on the progress of evaluable patients.  That seems to me a major concern. on the 30th March, 2023 MD & A we had 53 evaluable patients.
Check this link for their MD & A just over a year ago

https://theralase.com/wp-content/uploads/2023/08/MDA-Q123.pdf

After a full year, we have an evaluable patients at 63.   At the same rate we are going to need 4 more years to reach 100 evaluable patients.  RDW is talking about completing the clinical study by 2024 and possible commercialization by end 2026.  I am hoping taking on Dr. Jewet as a consultant would allow TLT to step on the Gas a bit.  I am hoping the during  the next month AUA meeting and Advisory board meeting with all TLT  principal investigators in the USA would get us some Tail wind and get it going in the right direction.

Just some wishfull thinking on a Lazy Sunday Afternoon.
<< Previous
Bullboard Posts
Next >>